{"id":"https://openalex.org/W7225916092","doi":"https://doi.org/10.6084/m9.figshare.34995719","title":"Relapse after omalizumab discontinuation in chronic spontaneous urticaria","display_name":"Relapse after omalizumab discontinuation in chronic spontaneous urticaria","publication_year":2026,"publication_date":"2026-11-12","ids":{"openalex":"https://openalex.org/W7225916092","doi":"https://doi.org/10.6084/m9.figshare.34995719"},"language":"en","primary_location":{"id":"doi:10.6084/m9.figshare.34995719","doi":"https://doi.org/10.6084/m9.figshare.34995719","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.34995719","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},"volume":null,"type":"dataset","is_traditional":false,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.6084/m9.figshare.34995719","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091475124","display_name":"Muhammed Burak Y\u00fccel","orcid":"https://orcid.org/0000-0003-0130-8229","observed_orcids":["https://orcid.org/0000-0003-0130-8229"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Muhammed Burak Y\u00fccel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5032167819","display_name":"Esranur \u00dcnal","orcid":"https://orcid.org/0000-0002-8309-6452","observed_orcids":["https://orcid.org/0000-0002-8309-6452"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Esranur \u00dcnal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12438","display_name":"Urticaria and Related Conditions","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12438","display_name":"Urticaria and Related Conditions","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11346","display_name":"Mast cells and histamine","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12600","display_name":"Eosinophilic Disorders and Syndromes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7519000172615051},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.7390000224113464},{"id":"https://openalex.org/C2778564945","wikidata":"https://www.wikidata.org/wiki/Q415392","display_name":"Omalizumab","level":4,"score":0.6578999757766724},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.5552999973297119},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48890000581741333},{"id":"https://openalex.org/C151956035","wikidata":"https://www.wikidata.org/wiki/Q1132755","display_name":"Logistic regression","level":2,"score":0.3734999895095825},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.3684000074863434},{"id":"https://openalex.org/C77350462","wikidata":"https://www.wikidata.org/wiki/Q1125472","display_name":"Confounding","level":2,"score":0.34150001406669617},{"id":"https://openalex.org/C70437156","wikidata":"https://www.wikidata.org/wiki/Q7228652","display_name":"Pooling","level":2,"score":0.3084000051021576},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.2881999909877777},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.28029999136924744},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.26829999685287476},{"id":"https://openalex.org/C2780648854","wikidata":"https://www.wikidata.org/wiki/Q2745824","display_name":"Immunopathology","level":2,"score":0.2567000091075897},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.25600001215934753},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.25440001487731934}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.6084/m9.figshare.34995719","doi":"https://doi.org/10.6084/m9.figshare.34995719","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.34995719","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.34995719.v1","doi":"https://doi.org/10.6084/m9.figshare.34995719.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.34995719.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"doi:10.6084/m9.figshare.34995719","doi":"https://doi.org/10.6084/m9.figshare.34995719","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.34995719","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Post-cessation":[0],"relapse":[1,17,47,153],"is":[2,158],"difficult":[3],"to":[4],"compare":[5],"because":[6],"patient":[7],"selection,":[8],"outcome":[9],"definitions":[10],"and":[11,23,26,37,56,61,70,129],"observation":[12],"periods":[13],"vary.":[14],"To":[15],"synthesize":[16],"after":[18,48,160],"omalizumab":[19],"cessation":[20,50],"in":[21,33],"CSU":[22],"CSU-predominant":[24],"cohorts":[25],"examine":[27],"interpretive":[28],"limitations.":[29],"We":[30],"updated":[31],"searches":[32],"PubMed,":[34],"Embase,":[35],"Scopus":[36],"Web":[38],"of":[39,86,175],"Science":[40],"on":[41],"23":[42],"October":[43],"2026.":[44],"Source-defined":[45],"clinical":[46],"complete":[49],"was":[51,144],"separated":[52],"from":[53],"taper":[54],"failure":[55],"retreatment.":[57],"Random-effects":[58],"logit":[59],"pooling":[60,98],"sensitivity":[62],"analyses":[63],"addressed":[64],"population,":[65],"response,":[66],"follow-up,":[67],"overlapping":[68],"reports":[69,117],"statistical":[71],"models.":[72],"Forty-one":[73],"stopping":[74,177],"risk":[75,124],"sets":[76,125,133],"(2,643":[77],"patients;":[78],"1,209":[79],"source-reported":[80],"events)":[81],"yielded":[82,139],"a":[83,110,172],"pooled":[84],"proportion":[85],"46.6%":[87],"(95%":[88,101],"CI":[89,102],"40.1\u201353.2%;":[90],"I2":[91],"=":[92],"87.7%;":[93],"prediction":[94],"interval":[95],"16.0\u201379.9%).":[96],"CSU-only":[97],"gave":[99],"47.1%":[100],"40.2\u201354.2%).":[103],"Results":[104],"reflect":[105],"different":[106],"follow-up":[107],"periods,":[108],"not":[109],"common":[111,159],"time-specific":[112],"risk.":[113],"Eighty-three":[114],"candidate":[115],"full":[116],"were":[118,155],"unavailable.":[119,156],"Three":[120],"newly":[121],"verified":[122],"small":[123],"contributed":[126],"0/1,":[127],"0/2":[128],"3/5":[130],"outcomes;":[131],"excluding":[132],"with":[134],"fewer":[135],"than":[136],"ten":[137],"stoppers":[138],"46.3%.":[140],"Pure":[141],"dose":[142],"reduction":[143],"supported":[145],"by":[146],"one":[147],"observational":[148],"arm.":[149],"Confirmed":[150],"type":[151],"IIb-specific":[152],"counts":[154],"Relapse":[157],"cessation,":[161],"but":[162],"high":[163],"heterogeneity":[164],"limits":[165],"individualized":[166],"prediction.":[167],"The":[168],"evidence":[169],"cannot":[170],"establish":[171],"causal":[173],"advantage":[174],"any":[176],"strategy":[178],"or":[179],"an":[180],"immune":[181],"endotype":[182],"for":[183],"recurrence.":[184]},"counts_by_year":[],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2026-11-13T00:00:00"}